Both products combine a long acting insulin with a GLP-1 analogue ... and weight gain compared to those taking Lantus. Analysts think this profile could give Xultophy an edge on its rival ...

Eli Lilly and Boehringer Ingelheim will undercut Sanofi by 15% with Basaglar, a biosimilar version of the insulin blockbuster Lantus launched today in the US. Basaglar will also undercut Sanofi ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

In July 2003. the company launched Lantus, the worlds first and only once a day insulin and in December 2003, Actonel, designed for the treatment of osteoporosis was launched.In the year 2004 ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...

NovoPen ®, the first insulin pen injector, was introduced in 1985. This article reviews the published evidence over two decades of use of the NovoPen ® family of injection devices in diabetes ...

Thus, by restoring a physiologic insulin profile, nateglinide essentially normalized glucose tolerance -- precisely what would be desired in an agent to be tested in a diabetes prevention study.

Insulin overdose symptoms can include confusion, fatigue, irritability, shaking, and other signs of low blood sugar (hypoglycemia). If you accidentally take too much or your blood sugar is low for ...

Build a custom area profile uses data from Nomis, an Office for National Statistics (ONS) service. Find all the data by visiting the Nomis website. The data and boundaries displayed in these profiles ...